Literature DB >> 8869216

Adult Still's disease: part I. Manifestations and complications in sixty-five cases in France.

C Masson1, X Le Loët, F Lioté, P Renou, J J Dubost, M C Boissier, L Brithmer, C Brégeon, M Audran.   

Abstract

DESIGN: a retrospective multicenter study conducted in France identified 65 cases of adult Still's disease. Data were recorded on a standardized questionnaire validated by the Inflammatory Joint Disease and Immunorheumatology Committee of the Société Française de Rhumatologie.
OBJECTIVES: (1) To compare clinical and laboratory findings in our patients with those reported in earlier studies, particularly two large series from Canada and Japan, respectively; (2) to describe the systemic and visceral complications associated with adult Still's disease.
RESULTS: as compared with the two above-mentioned series, our study group included more patients who had experienced onset of their disease after the age of 35 years and fewer patients with involvement of the liver, spleen, or lymph nodes. Rates of occurrence of arthritis, myalgia, sore throat, pleuritis, pericarditis, and abdominal pain were significantly higher in the Canadian series than in the other two series. Arthritis was absent in one fourth of our patients. Life-threatening complications included "Still's hepatopathy", disseminated intravascular coagulation (with hemophagocytosis in some cases), and "Still's myocarditis".
CONCLUSION: differences in the expression of adult Still's disease were found between patients from Canada, France, and Japan. Adult Still's disease can be responsible for life-threatening complications.

Entities:  

Mesh:

Year:  1995        PMID: 8869216

Source DB:  PubMed          Journal:  Rev Rhum Engl Ed        ISSN: 1169-8446


  15 in total

1.  Sore throat and hyperferritinaemia.

Authors:  J Kelly; P Chowienczyk; T Gibson
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

2.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

Review 3.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

4.  Adult-onset Still's disease revealed by perimyocarditis and a concomitant reactivation of an EBV infection.

Authors:  Roderich Meckenstock; Audrey Therby; Geraldine Gibault-Genty; David Khau; Sebastien Monnier; Alix Greder-Belan
Journal:  BMJ Case Rep       Date:  2012-11-19

5.  Adult Onset Still's Disease and Rocky Mountain Spotted Fever.

Authors:  Paul Persad; Rajendrakumar Patel; Niki Patel
Journal:  Case Rep Med       Date:  2010-08-09

6.  Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation.

Authors:  Matteo Colina; Marcello Govoni; Francesco Trotta
Journal:  Rheumatol Int       Date:  2008-12-02       Impact factor: 2.631

Review 7.  Cutaneous manifestations of adult-onset Still's disease: a case report and review of literature.

Authors:  Alessandra Cozzi; Anastasia Papagrigoraki; Domenico Biasi; Chiara Colato; Giampiero Girolomoni
Journal:  Clin Rheumatol       Date:  2014-04-17       Impact factor: 2.980

Review 8.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Is Still's disease still one disease? A case of Adult-onset Still's disease showing accumulation in the carotids and the large vessels of the legs on positron emission tomography: CT images.

Authors:  L C G de Graaff; M R J ten Broek; D H Schweitzer
Journal:  Rheumatol Int       Date:  2011-07-21       Impact factor: 3.580

Review 10.  Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.

Authors:  Zoltán Szekanecz; Iain B McInnes; Georg Schett; Szilvia Szamosi; Szilvia Benkő; Gabriella Szűcs
Journal:  Nat Rev Rheumatol       Date:  2021-08-02       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.